Homegrown private equity firm Samara Capital has emerged as one of the frontrunners to invest in a Mumbai-based pharmaceutical development and manufacturing company, two people ..
Bain Capital is the likely frontrunner to acquire stake in TPG Capital-backed Sai Life Sciences, a Hyderabad-based contract research, development, and manufacturing organisation, a media ..
US buyout fund Platinum Equity Advisors is in talks to acquire Mumbai-based contract drugmaker Inventia Healthcare at a valuation of ₹2,500 crore ($300 million). Existing investors InvAscent Capital and Jacob Ballas are set to exit their investments while promoter Janak Shah and family will retain a minority stake. Post the transaction, the promoter family intends to continue leading the company. Rothschild & Co and Stifel Financial Corp are running the sale process of Inventia.
Urinary Retention Therapeutics IndustryThe global urinary retention therapeutics industry size is anticipated to attain an impressive valuation of US$ 3.44 billion in 2023 and is projected to reach US$ 7.5 billion by 2033, expected to register a CAGR of 8.11% until 2033, as per a recently published Future Market Ins.
Multiple private equity players including Apax Partners, TPG Capital, TA Associates and Kedaara Capital are in early talks to buy a Mumbai-based pharma company that ..